Ester Mínguez de la Guía

Ester Mínguez de la Guía

Auto-generated profile, based on publicly available information

Ester Mínguez de la Guía

Cardiology Department, University Hospital of Albacete, Spain (E.M.d.l.G., M.L.V., F.S.M., M.C.-P.)

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2026 in Circulation
Verified
Journal Article
Closed access
SRSergio Raposeiras-Roubín
Sergio Raposeiras-Roubín
EAEmad Abu Assi
Emad Abu Assi
CMCésar Jiménez Méndez
César Jiménez Méndez
EGEster Mínguez de la Guía
Ester Mínguez de la Guía
JPJose-Angel Perez-Rivera
Jose-Angel Perez-Rivera
AAAlbert Ariza-Solé
Albert Ariza-Solé
BACKGROUND: Current guidelines recommend a stepwise strategy to achieve low-density lipoprotein cholesterol (LDL-C) goals after acute coronary syndrome (ACS). Earlier intensive strategies based on a combination of lipid-lowering therapies (LLTs) could be useful from the onset of ACS. However, the role of bempedoic acid in ACS, particularly when combined with high-intensity statins and ezetimibe, remains uncertain. The aim of ES-BempedACS (Efficacy and Security of Bempedoic Acid in Acute Coronary Syndrome) was to compare the efficacy and safety of triple LLT (high-dose, high-intensity statin+ezetimibe+bempedoic acid) versus standard of care (high-dose, high-intensity statin+ezetimibe) after ACS. METHODS: ES-BempedACS is a multicenter, independent, pragmatic, prospective, randomized, open, blinded end point controlled trial conducted in 12 Spanish hospitals between November 2023 and October 2024. The primary end point was the proportion of patients achieving LDL-C <55 mg/dL (<1.4 mmol/L) at 8 weeks after ACS, comparing triple LLT with standard of care. RESULTS: A total of 206 patients (59.5±10.9 years of age [mean±SD]; 21.4% women) were randomized within the first 72 hours of ACS to triple LLT or standard therapy of high-intensity statin+ezetimibe (ie, dual LLT). The baseline LDL-C level was 133.6±28.8 mg/dL. After 8 weeks, the LDL-C level was reduced to 50%) of adequate LDL-C control (<55 mg/dL) at 8 weeks. Adding bempedoic acid to statin–ezetimibe therapy in the setting of ACS is safe but failed to improve the percentage of patients achieving the LDL-C goal (<55 mg/dL) at 8 weeks. Larger, randomized studies are needed to confirm our findings. REGISTRATION: URL: https://www.clinicaltrialsregister.eu ; Unique identifier: 2021-006550-31.

12 January 2026 in REC: CardioClinics
Verified
Journal Article
Closed access
EGEster Mínguez de la Guía
Ester Mínguez de la Guía
MVMacarena López Vázquez
Macarena López Vázquez
JSJulia Piñana Sendra
Julia Piñana Sendra
MSMaría Isabel Barrionuevo Sánchez
María Isabel Barrionuevo Sánchez
FMFrancisco Manuel Salmerón Martínez
Francisco Manuel Salmerón Martínez
MPMiguel José Corbí Pascual
Miguel José Corbí Pascual